丹纳赫预计业绩将达先前指引高端

Core Insights - Danaher expects strong performance in its bioprocessing business to drive revenue growth in Q4 and bring annual earnings close to the upper limit of previous forecasts [1][1] - The company anticipates adjusted core revenue growth in Q4 to approach the upper limit of its previously stated low single-digit percentage growth forecast [1][1] - For the fiscal year 2025, Danaher projects adjusted earnings per share to be near the upper end of the prior forecast range of $7.70 to $7.80 [1][1] - CEO Rainer Blair expressed satisfaction with the continued strong performance of the bioprocessing business and better-than-expected revenue in the life sciences and diagnostics segments [1][1]